Home » EraGen Partners with Illumina to Develop Molecular Dx Assays

EraGen Partners with Illumina to Develop Molecular Dx Assays

Nov 18, 2009

NEW YORK (GenomeWeb News) – EraGen Biosciences said today that it has formed a strategic partnership with Illumina to develop high-throughput, multiplexed clinical assays.

Under the agreement, EraGen, based in Madison, Wis., has non-exclusively licensed the use of Illumina's BeadXpress platform to develop and commercialize molecular-based, high-throughput, clinical assays using EraGen's MultiCode-PLx technology.

Meantime, Illumina has non-exclusively licensed EraGen's MultiCode-PLx technology for the life sciences, research, and clinical markets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Articles

Mar 11, 2014

Enzo Biochem Posts 3 Percent Revenue Gain for Q2

Aug 28, 2014

Atossa Subsidiary NRLBH, BioVentive Ink Marketing Deal

Apr 09, 2014

BioTheranostics Inks Contract with PPO Prime Health Services

Oct 29, 2014

Chinese Firm Builds Genomics Facility for Translational Research with PacBio as Major Platform

Premium
Apr 15, 2014

French Researchers Develop Automated, Array-based Molecular Blood Group Typing Technique

Premium
May 09, 2011

Akonni, Seegene Ink MDx Collaboration

The Scan

This Week in Genome Research

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

To the Brink

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Just Like Your Old Pop

Researchers report that paternally inherited genes are more likely to be expressed in mice.

What We'd Do With the Money

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

What's Popular?

In Clinical & Translational

  1. Oncotype DX Study Raises Questions About RT-PCR Testing for HER2 Expression

    Premium

  2. Sysmex Inostics, Merck Aim for 2015 CE Mark for ctDNA Kit for Metastatic Colorectal Cancer

    Premium

  3. Alere Developing Pair of NAT Platforms with Initial Assays Planned for HIV Viral Load, Flu

    Premium

  4. Ariosa Study Finds Arrays Deliver 'More Accurate' NIPT Results than NGS in Shorter Time

    Premium

  5. Contextual Genomics, Personalized Medicine Initiative Launch Tumor Profiling Project in Canada

Sponsorships

Privacy Policy.  Copyright © 2015 Genomeweb LLC.  All Rights Reserved.